Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03273049 · ClinicalTrials.gov registry record

Mapping Disease Pathways for Biliary Atresia

A clinical trial of Biliary Atresia, sponsored by University of Pittsburgh.

Recruiting
Registry status
1,100
Enrollment target
1
Study location

NCT03273049 is a study of Biliary Atresia that is actively recruiting participants, run by University of Pittsburgh. The registered enrollment target is 1,100 participants, above the 418-participant average among 7 other Biliary Atresia trials with a reported enrollment target (163% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03273049, a study of Biliary Atresia, is actively recruiting participants, sponsored by University of Pittsburgh.

RECRUITING
Registry status
1,100 participants
Enrollment target
1
Study location

Study Summary

This project will primarily evaluate the developmental/genetic basis of biliary atresia, the most common cause of liver failure at birth, and which accounts of half of all liver transplants performed worldwide in children.

Conditions Studied

Study Locations (1)

Pennsylvania

  • UPMC Children's Hospital of Pittsburgh - Pittsburgh

Trial Details

FieldValue
Enrollment Target 1,100 participants
Start Date 2016-07-21
Est. Completion 2035-07-21

Sponsor

University of Pittsburgh

1,238 total trials

What the Registry Record Tells You About NCT03273049

The ClinicalTrials.gov registry entry for NCT03273049 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,100 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 418-participant average among 7 other Biliary Atresia trials with a reported enrollment target (163% higher). The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Biliary Atresia appearing as the primary indexed condition, and to 0 interventions.

NCT03273049 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03273049 about?

NCT03273049 is a clinical study titled "Mapping Disease Pathways for Biliary Atresia". This project will primarily evaluate the developmental/genetic basis of biliary atresia, the most common cause of liver failure at birth, and which accounts of half of all liver transplants performed worldwide in children.

What is the current status of trial NCT03273049?

This trial is currently recruiting. The enrollment target is 1,100 participants. The study started on 2016-07-21. Estimated completion is 2035-07-21.

What conditions does trial NCT03273049 study?

This clinical trial studies the following conditions: Biliary Atresia.

Who is sponsoring clinical trial NCT03273049?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03273049 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Biliary Atresia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.